Terry L. Smith

21.1k total citations · 5 hit papers
154 papers, 16.0k citations indexed

About

Terry L. Smith is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Terry L. Smith has authored 154 papers receiving a total of 16.0k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Oncology, 44 papers in Cancer Research and 42 papers in Pathology and Forensic Medicine. Recurrent topics in Terry L. Smith's work include Breast Cancer Treatment Studies (40 papers), Acute Myeloid Leukemia Research (28 papers) and Cancer Treatment and Pharmacology (26 papers). Terry L. Smith is often cited by papers focused on Breast Cancer Treatment Studies (40 papers), Acute Myeloid Leukemia Research (28 papers) and Cancer Treatment and Pharmacology (26 papers). Terry L. Smith collaborates with scholars based in United States, United Kingdom and Türkiye. Terry L. Smith's co-authors include M. Schemper, Aman U. Buzdar, Gabriel N. Hortobágyi, Michael J. Keating, Hagop M. Kantarjian, Emil J. Freireich, Richard L. Theriault, S. Eva Singletary, Ying Yang and George R. Blumenschein and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Investigation.

In The Last Decade

Terry L. Smith

153 papers receiving 15.5k citations

Hit Papers

A note on quantifying fol... 1996 2026 2006 2016 1996 1999 2005 1996 2000 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A note on quantifying follow-up in studies of failure time
    1996 1.9k citations Terry L. Smith et al. profile →
  2. Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy
    1999 1.1k citations Terry L. Smith, Kelly K. Hunt et al. Journal of Clinical Oncology profile →
  3. Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer
    2005 867 citations Aman U. Buzdar, Nuhad K. Ibrahim et al. Journal of Clinical Oncology profile →
  4. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.
    1996 596 citations Gabriel N. Hortobágyi, Terry L. Smith et al. Journal of Clinical Oncology profile →
  5. Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia
    2000 586 citations Hagop M. Kantarjian, Terry L. Smith et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Terry L. Smith 7.7k 4.2k 3.6k 2.9k 2.8k 154 16.0k
Gianni Bonadonna 11.3k 1.5× 5.9k 1.4× 2.6k 0.7× 7.5k 2.6× 2.1k 0.8× 373 20.2k
Naoto T. Ueno 11.0k 1.4× 6.5k 1.5× 3.3k 0.9× 2.2k 0.8× 5.6k 2.0× 547 20.4k
Richard Greil 10.9k 1.4× 3.9k 0.9× 2.3k 0.6× 4.2k 1.5× 5.3k 1.9× 731 20.1k
Rosemarie Mick 6.2k 0.8× 2.1k 0.5× 1.5k 0.4× 1.5k 0.5× 3.5k 1.3× 265 14.4k
Apostolia M. Tsimberidou 5.4k 0.7× 4.2k 1.0× 1.7k 0.5× 3.4k 1.2× 4.8k 1.7× 445 14.5k
George P. Canellos 6.0k 0.8× 1.3k 0.3× 2.1k 0.6× 8.0k 2.8× 1.6k 0.6× 209 15.8k
Mark Krailo 5.7k 0.7× 2.0k 0.5× 1.3k 0.4× 2.7k 1.0× 4.5k 1.6× 392 18.7k
Massimo Aglietta 7.1k 0.9× 1.9k 0.5× 2.4k 0.7× 1.6k 0.6× 3.6k 1.3× 397 14.5k
Thierry Philip 4.8k 0.6× 1.1k 0.3× 1.7k 0.5× 4.6k 1.6× 2.3k 0.8× 277 12.0k
Christoph Zielinski 10.1k 1.3× 2.6k 0.6× 2.0k 0.6× 1.4k 0.5× 5.0k 1.8× 499 20.8k

Countries citing papers authored by Terry L. Smith

Since Specialization
Citations

This map shows the geographic impact of Terry L. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terry L. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terry L. Smith more than expected).

Fields of papers citing papers by Terry L. Smith

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Terry L. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terry L. Smith. The network helps show where Terry L. Smith may publish in the future.

Co-authorship network of co-authors of Terry L. Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Terry L. Smith. A scholar is included among the top collaborators of Terry L. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Terry L. Smith. Terry L. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schurman, Lesley D., Terry L. Smith, Giulia Donvito, et al.. (2021). Diacylglycerol Lipase-β Knockout Mice Display a Sex-Dependent Attenuation of Traumatic Brain Injury-Induced Mortality with No Impact on Memory or Other Functional Consequences. Cannabis and Cannabinoid Research. 6(6). 508–521. 3 indexed citations
2.
Powell, Melissa A., et al.. (2018). Matrix Metalloproteinase 9 and Osteopontin Interact to Support Synaptogenesis in the Olfactory Bulb after Mild Traumatic Brain Injury. Journal of Neurotrauma. 36(10). 1615–1631. 11 indexed citations
3.
Powell, Melissa A., et al.. (2017). Mild Fluid Percussion Injury Induces Diffuse Axonal Damage and Reactive Synaptic Plasticity in the Mouse Olfactory Bulb. Neuroscience. 371. 106–118. 8 indexed citations
4.
Buzdar, Aman U., Nuhad K. Ibrahim, Daniel J. Booser, et al.. (2005). Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer. Journal of Clinical Oncology. 23(16). 3676–3685. 867 indexed citations breakdown →
5.
Escalón, Maricer P., Ying Yang, Mark A. Hess, et al.. (2005). Prognostic factors and treatment of patients with T‐cell non‐Hodgkin lymphoma. Cancer. 103(10). 2091–2098. 169 indexed citations
6.
7.
Duvic, Madeleine, Narin Apisarnthanarax, Deborah S. Cohen, et al.. (2003). Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology. 49(1). 35–49. 48 indexed citations
8.
Esteva, Francisco J., Ayşegül A. Şahin, George Z. Rassidakis, et al.. (2003). Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.. PubMed. 9(15). 5652–9. 63 indexed citations
9.
Yang, Wentao, Kristine S. Klos, Xiaoyan Zhou, et al.. (2003). ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up‐regulation and tyrosine‐15 hyperphosphorylation of p34Cdc2. Cancer. 98(6). 1123–1130. 33 indexed citations
10.
Vassilopoulou‐Sellin, Rena, Deborah S. Cohen, Gabriel N. Hortobágyi, et al.. (2002). Estrogen replacement therapy for menopausal women with a history of breast carcinoma. Cancer. 95(9). 1817–1826. 38 indexed citations
11.
Kim, Young Sil, Sergej Konoplev, Filippo Montemurro, et al.. (2001). HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.. PubMed. 7(12). 4008–12. 33 indexed citations
12.
Keating, Michael J., Terry L. Smith, Susan Lerner, et al.. (2000). Prediction of Prognosis Following Fludarabine Used as Secondary Therapy for Chronic Lymphocytic Leukemia. Leukemia & lymphoma. 37(1-2). 71–85. 29 indexed citations
13.
Ha, Chul S., Vivek S. Kavadi, Meletios Α. Dimopoulos, et al.. (1999). Hodgkin’s disease with lymphocyte predominance: long-term results based on current histopathologic criteria. International Journal of Radiation Oncology*Biology*Physics. 43(2). 329–334. 16 indexed citations
14.
15.
Tuttle, Todd M., Jeffrey E. Lee, Ayşegül A. Şahin, et al.. (1998). Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients.. PubMed. 4(8). 2015–24. 44 indexed citations
16.
Majlis, Alejandro, Terry L. Smith, Moshe Talpaz, et al.. (1996). Significance of cytogenetic clonal evolution in chronic myelogenous leukemia.. Journal of Clinical Oncology. 14(1). 196–203. 63 indexed citations
17.
Smith, Terry L., J. Jack Lee, Hagop M. Kantarjian, Sewa S. Legha, & Martin N. Raber. (1996). Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center.. Journal of Clinical Oncology. 14(1). 287–295. 63 indexed citations
18.
Eifel, Patricia J., Thomas W. Burke, Michael B. Morris, & Terry L. Smith. (1995). Adenocarcinoma as an Independent Risk Factor for Disease Recurrence in Patients with Stage IB Cervical Carcinoma. Gynecologic Oncology. 59(1). 38–44. 211 indexed citations
19.
Logothetis, Christopher J., Elizabeth Hossan, & Terry L. Smith. (1994). SMS 201-995 in the treatment of refractory prostatic carcinoma.. PubMed. 14(6B). 2731–4. 33 indexed citations
20.
Samuels, M. L., et al.. (1975). Combination chemotherapy with bleomycin (NSC-125066), vincristine (NSC-67574), and methotrexate (NSC-740) plus split-course radiotherapy in the treatment of non-oat-cell bronchogenic carcinoma.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 59(2 Pt 1). 377–83. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gianni Bonadonna Breakdown of academic impact, for papers by Naoto T. Ueno Breakdown of academic impact, for papers by Richard Greil Breakdown of academic impact, for papers by Rosemarie Mick Breakdown of academic impact, for papers by Apostolia M. Tsimberidou Breakdown of academic impact, for papers by George P. Canellos Breakdown of academic impact, for papers by Mark Krailo Breakdown of academic impact, for papers by Massimo Aglietta Breakdown of academic impact, for papers by Thierry Philip Breakdown of academic impact, for papers by Christoph Zielinski
Rankless by CCL
2026